NEW YORK, May 19, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 14, 2025.So What: If you purchased Iovance securities during the Class Period y ...

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for misleading statements made during the Class Period from May 9, 2024, to May 8, 2025, potentially affecting investors' financial interests [1][4]. Group 1: Lawsuit Details - The lawsuit alleges that Iovance made false and misleading statements regarding the effectiveness of new Authorized Treatment Centers (ATCs) in treating patients with Amtagvi, leading to longer timelines and higher patient drop-offs [4]. - It is claimed that these issues resulted in increased costs and decreased revenue for Iovance, contradicting the company's positive statements about its business and operations [4]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors in this case, highlighting its track record of recovering significant amounts for investors [5]. - Investors are advised to select qualified legal counsel with a proven history in leadership roles within class actions [5]. - The firm has achieved notable settlements, including over $438 million for investors in 2019 alone, and has been consistently ranked among the top firms in securities class action settlements [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Iovance Biotherapeutics, Inc. due to significant declines in revenue and misleading statements made by the company regarding its business operations and prospects [2][4]. Financial Performance - Iovance reported a quarterly total product revenue of $49.3 million for Q1 2025, down from $73.7 million in the previous quarter, indicating a substantial decline [5]. - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [5]. Legal Proceedings - A federal securities class action has been filed against Iovance, with a deadline of July 14, 2025, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that Iovance made materially false and misleading statements and failed to disclose adverse facts about its business, including issues with new Authorized Treatment Centers (ATCs) and patient treatment timelines [4]. Market Reaction - Following the release of the disappointing financial results, Iovance's share price fell by $1.42, or 44.8%, closing at $1.75 per share on May 9, 2025, with unusually high trading volume [6].

Core Viewpoint - Julie & Holleman LLP is investigating potential claims against Iovance Biotherapeutics, Inc. and its executives due to recent losses suffered by the company's stockholders [1][2]. Group 1: Legal Investigation - A complaint filed in federal court alleges that Iovance and its executives misled investors by exaggerating the company's financial prospects and downplaying risk factors affecting growth potential [2]. - The complaint specifically claims that the company concealed its inability to generate demand and was ill-equipped to capitalize on existing demand for its treatments through its network of approved treatment centers [2]. Group 2: Firm Background - Julie & Holleman LLP is a boutique law firm specializing in shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations [4]. - The firm's attorneys have a track record of securing hundreds of millions of dollars for aggrieved companies and their shareholders [4].

Core Points - A class action has been filed against Iovance Biotherapeutics, Inc. for allegedly misleading investors regarding its business prospects during the class period from May 9, 2024, to May 8, 2025 [1][2] - The complaint highlights several issues, including delays in treatment timelines at new Authorized Treatment Centers (ATCs), ineffective patient identification and selection, and the resulting higher costs and lower revenue [2] - Iovance reported a significant decline in quarterly product revenue, dropping from $73.7 million to $49.3 million, and revised its full-year revenue guidance down by over 40% [3] Company Performance - Iovance's first quarter 2025 financial results showed total product revenue of $49.3 million, a decrease of approximately 33% from the previous quarter [3] - The company's full fiscal year 2025 revenue guidance was reduced from a range of $450 million - $475 million to $250 million - $300 million, indicating a substantial downward revision [3] Legal Proceedings - Shareholders interested in participating in the class action must file their papers by July 14, 2025, to serve as lead plaintiff [4] - The class action allows shareholders to recover losses without needing to actively participate in the case [4]

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for allegedly providing misleading statements about its growth potential and failing to capitalize on demand for its treatments during the class period from May 9, 2024, to May 8, 2025 [1][3]. Company Performance - Iovance announced its financial results for Q2 2024 on July 25, 2024, and reduced its revenue guidance for the full fiscal year 2024 due to several factors, including maintenance that reduced capacity, lower-than-expected Proleukin sales, and the variable pace of treatment initiation [4]. - Following the announcement of reduced guidance, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [4]. Legal Proceedings - The lawsuit is on behalf of all individuals and entities that purchased Iovance securities during the specified class period, with a deadline of July 14, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that the company concealed material adverse facts regarding its ability to meet demand for its treatments [3]. Investor Information - Investors who suffered losses or have questions regarding the lawsuit can contact the law firm Bragar Eagel & Squire, P.C. for more information [5].

Core Viewpoint - A securities class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for allegedly misleading investors regarding the company's performance and treatment timelines for its product Amtagvi during the class period from May 9, 2024, to May 8, 2025 [1][2]. Group 1: Allegations and Company Performance - The lawsuit claims that Iovance made false statements and failed to disclose critical issues, including delays in treatment timelines at new Authorized Treatment Centers (ATCs) and inefficiencies in patient identification, leading to increased costs and reduced revenue [2]. - Iovance reported a significant decline in quarterly total product revenue, dropping to $49.3 million from $73.7 million in the previous quarter, and slashed its full fiscal year 2025 revenue guidance from $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [3]. - Following the release of these financial results, Iovance's share price fell by $1.42, or 44.8%, closing at $1.75 per share on May 9, 2025, amid unusually high trading volume [3]. Group 2: Legal Proceedings - Investors who acquired shares of Iovance during the class period are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline of July 15, 2025 [4].

Core Viewpoint - Iovance Biotherapeutics experienced a nearly 6% decline in stock price due to a downgrade in analyst recommendation, despite a generally positive market day for equities [1]. Group 1: Analyst Downgrade - UBS analyst David Dai changed his recommendation for Iovance from buy to neutral and significantly lowered the price target from $17 to $2 per share [2]. - This downgrade followed the release of the company's latest quarterly earnings, which provided insights into its performance [4]. Group 2: Product Performance Concerns - Sales of Iovance's leading product, the advanced melanoma drug Amtagvi, were reported to be below expectations, indicating a slower commercialization ramp-up [5]. - There are concerns regarding higher drop-out rates for Amtagvi, suggesting potential flaws in patient selection [5]. Group 3: Revenue Guidance and Market Sentiment - The company issued a notable revenue guidance cut in its earnings report, raising concerns among investors about its future performance [6]. - Despite the scientific potential of Iovance and Amtagvi, the current business aspects warrant caution among investors [6].

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for alleged violations of federal securities laws, following a significant decline in the company's financial performance and misleading statements made to investors [1][2][3]. Financial Performance - Iovance reported a total product revenue of $49.3 million for Q1 2025, down from $73.7 million in the previous quarter [4]. - The company's full fiscal year 2025 revenue guidance was reduced from $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [4]. Allegations - The lawsuit claims that Iovance's executives provided overly positive statements while concealing material adverse facts about the company's growth potential and its ability to meet demand for its treatments [3]. Legal Proceedings - Investors who purchased Iovance securities between May 9, 2024, and May 8, 2025, are encouraged to join the class action lawsuit, with a deadline to request lead plaintiff status by July 14, 2025 [2][5]. Representation - Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis, meaning they will only collect fees if the case is successful [6][7].

Group 1 - A shareholder class action lawsuit has been filed against Iovance Biotherapeutics, alleging materially false and misleading statements regarding the company's business and operations [1] - The lawsuit claims that new Authorized Treatment Centers (ATCs) are facing longer timelines to begin treating patients with Amtagvi, which has led to inefficiencies in patient identification and selection [1] - These dynamics have resulted in higher costs and lower revenue for Iovance, as ATCs are unable to keep pace with the manufactured product [1] Group 2 - Shareholders who purchased Iovance shares between May 9, 2024, and May 8, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request appointment as lead plaintiff in the case is July 14, 2025 [3] - Holzer & Holzer, LLC is a law firm specializing in securities litigation and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]